Literature DB >> 12107108

Nitric oxide modulates vascular disease in the remnant kidney model.

Duk-Hee Kang1, Takahiko Nakagawa, Lili Feng, Richard J Johnson.   

Abstract

A loss of the microvascular endothelium occurs in the remnant kidney model of renal disease and may play an important role in progression (Kang et al, J Am Soc Nephrol, 12:1434, 2001). Given that nitric oxide (NO) is a potent endothelial cell survival factor, we hypothesized that stimulating (with L-arginine) or blocking (with nitro-L-arginine methyl ester, (L-NAME)) NO synthesis could modulate the integrity of the microvasculature and hence affect progression of renal disease. Rats underwent 5/6 nephrectomy (RK) and then were randomized at 4 weeks to receive vehicle, L-NAME, or L-arginine for 4 weeks. Systolic blood pressure and renal function was measured, and tissues were collected at 8 weeks for histological and molecular analyses. The effect of modulation of NO on vascular endothelial growth factor (VEGF) expression in rat aortic vascular smooth muscle cells (SMC) and mouse medullary thick ascending limb tubular epithelial cells (mTAL) was also studied. Inhibition of NO with L-NAME was associated with more rapid progression compared to RK alone, with worse blood pressure, proteinuria, renal function, glomerulosclerosis, and tubulointerstitial fibrosis. The injury was also associated with more glomerular and peritubular capillary endothelial cell loss in association with an impaired endothelial proliferative response. Interestingly, the preglomerular endothelium remained intact or was occasionally hyperplastic, and this was associated with a pronounced proliferation of the vascular SMCs with de novo expression of VEGF. Cell culture studies confirmed a divergent effect of NO inhibition on VEGF expression, with inhibition of VEGF synthesis in mTAL cells and stimulation of VEGF in vascular SMC. In contrast to the effects of NO inhibition, stimulation of NO with L-arginine had minimal effects in this rat model of progressive renal disease. These studies confirm that blockade of NO synthesis accelerates progression of renal disease in the remnant kidney model, and support the hypothesis that one of the pathogenic mechanisms may involve accelerated capillary loss and impaired angiogenesis of the renal microvasculature. Interestingly, inhibition of NO synthesis did not lead to a loss of the preglomerular endothelium, which may relate to the effect of NO blockade to stimulate VEGF synthesis in the adjacent vascular smooth muscle cell.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107108      PMCID: PMC1850677          DOI: 10.1016/S0002-9440(10)64175-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

Review 1.  Chronic nitric oxide inhibition model six years on.

Authors:  R Zatz; C Baylis
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

2.  The vascular pole of the renal glomerulus of rat.

Authors:  M Elger; T Sakai; W Kriz
Journal:  Adv Anat Embryol Cell Biol       Date:  1998       Impact factor: 1.231

Review 3.  Nitric oxide in renal health and disease.

Authors:  B C Kone
Journal:  Am J Kidney Dis       Date:  1997-09       Impact factor: 8.860

4.  Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure.

Authors:  L De Nicola; V Bellizzi; R Minutolo; M Andreucci; A Capuano; G Garibotto; G Corso; V E Andreucci; B Cianciaruso
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

5.  Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.

Authors:  A Benigni; C Zoja; M Noris; D Corna; G Benedetti; I Bruzzi; M Todeschini; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1999-04       Impact factor: 8.860

6.  Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations.

Authors:  A M Verhagen; B Braam; P Boer; H J Gröne; H A Koomans; J A Joles
Journal:  Kidney Int       Date:  1999-07       Impact factor: 10.612

7.  Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors.

Authors:  L C Jadeski; P K Lala
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.

Authors:  T Murohara; T Asahara; M Silver; C Bauters; H Masuda; C Kalka; M Kearney; D Chen; J F Symes; M C Fishman; P L Huang; J M Isner
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

9.  Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model.

Authors:  H Kitamura; A Shimizu; Y Masuda; M Ishizaki; Y Sugisaki; N Yamanaka
Journal:  Exp Nephrol       Date:  1998 Jul-Aug

10.  Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin.

Authors:  C Chatziantoniou; J J Boffa; R Ardaillou; J C Dussaule
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

View more
  32 in total

1.  Large BP-dependent and -independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers.

Authors:  Karen Griffin; Aaron Polichnowski; Hector Licea-Vargas; Maria Picken; Jianrui Long; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

2.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

Review 3.  Microvascular rarefaction: the decline and fall of blood vessels.

Authors:  Michael S Goligorsky
Journal:  Organogenesis       Date:  2010 Jan-Mar       Impact factor: 2.500

Review 4.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.

Authors:  Imari Mimura; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

5.  Inducible nitric oxide synthase modulates hydronephrosis following partial or complete unilateral ureteral obstruction in the neonatal mouse.

Authors:  Kee Hwan Yoo; Barbara A Thornhill; Michael S Forbes; Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-04

6.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

7.  Hypoxia in renal disease with proteinuria and/or glomerular hypertension.

Authors:  Tetsuhiro Tanaka; Toshio Miyata; Reiko Inagi; Toshiro Fujita; Masaomi Nangaku
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

9.  Effects of 5/6 nephrectomy on renal function and blood pressure in mice.

Authors:  Agata L Gava; Flavia Ps Freitas; Camille M Balarini; Elisardo C Vasquez; Silvana S Meyrelles
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20

Review 10.  Emerging risk factors and markers of chronic kidney disease progression.

Authors:  Florian Kronenberg
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.